Drug news
NICE rejects Provenge as a treatment for Prostate Cancer- Dendreon
The National Institute for Health and Care Excellence (NICE) has decided not to recommend Provenge (sipuleucel-T) from Dendreon for the treatment of metastatic Prostate Cancer prior to chemotherapy. The agency found a lack of evidence to support the product as cost-effective. The drug was not known to delay the progression of the disease compared to current treatments although there was an improvement in overall survival compared to placebo.